Urinary rituximab loss and rate of treatment failure in membranous nephropathy
In primary membranous nephropathy, urinary rituximab loss is associated with disease severity, drug underexposure, and treatment failure. Measuring urinary rituximab could help identify patients at risk of resistance who could benefit from additional rituximab dosing. This approach could improve outcome prediction and support personalized immunosuppressive strategies.
Authors
- Alessandra Vultaggio (ORCID: https://orcid.org/0000-0002-8775-9217)
- Lorenzo Cosmi (ORCID: https://orcid.org/0000-0002-8150-8177)
- Andrea Matucci (ORCID: https://orcid.org/0000-0002-3499-992X)
- Tommaso Mazzierli
- Matteo Accinno
- Leonardo Caroti (ORCID: https://orcid.org/0000-0002-0612-3517)
- Cinzia Finocchi (ORCID: https://orcid.org/0000-0003-4385-1203)
- Marco Del Carria (ORCID: https://orcid.org/0009-0007-0955-2417)
- Marco Allinovi (ORCID: https://orcid.org/0000-0001-9949-3543)
- Calogero Lino Cirami (ORCID: https://orcid.org/0000-0002-3776-4691)
- Francesco Peyronel (ORCID: https://orcid.org/0000-0001-8470-1952)
- Daniela Lazzarini
- Michael Diomaiuti
Institutions
- Azienda Ospedaliero-Universitaria Careggi (IT)
- University of Florence (IT)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2025-07-04
- DOI
- https://doi.org/10.1093/ndt/gfaf127
- Citations
- 6
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 8.58